James Hickman,
Professor, Nanoscience Technology, Chemistry, Biomolecular Science and Electrical Engineering,
University of Central Florida; Chief Scientist, Hesperos
James J. Hickman is the Founding Director of the NanoScience Technology Center and a Professor of Nanoscience Technology, Chemistry, Biomolecular Science, Biomedical Engineering, Material Science and Electrical Engineering at the University of Central Florida. Previously, he held the position of the Hunter Endowed Chair in the Bioengineering Department at Clemson University. Dr. Hickman has a Ph.D. from the Massachusetts Institute of Technology in Chemistry. For the past thirty years, he has been studying the interaction of biological species with modified surfaces, first in industry and in the latter years in academia. While in industry he established one of the first bioelectronics labs in the country that focused on cell-based sensors and their integration with electronic devices and MEMS devices. He is interested in creating hybrid systems for biosensor and biological computation applications and the creation of functional in vitro systems for human body-on-a-chip applications. He has worked at NSF and DARPA in the area of biological computation. He is also the founder and current Chief Scientist of a biotechnology company, Hesperos, that is focusing on cell-based systems for drug discovery and toxicity. He has 166 publications and 20 book chapters, in addition to 34 issued patents out of 50 total patent applications. He was elected to the Board of Directors of the American Institute for Medical and Biological Engineering (AIMBE) for 2 consecutive terms, the premier society for Biomedical Engineering of which he is a Fellow. He is also a Fellow of the American Vacuum Society (AVS) and National Academy of Inventors (NAI) as well as BioFlorida’s Researcher of the Year (2022). Dr. Hickman along with Dr. Michael Shuler, won the Lush Prize, in the Science Category, which Supports Animal Free Testing in 2015.
Utilizing Multi-Organ Human on a Chip Systems to Predict in vivo Outcomes For Efficacy and Toxicity
Thursday, 13 June 2019 at 10:45
Add to Calendar ▼2019-06-13 10:45:002019-06-13 11:45:00Europe/LondonUtilizing Multi-Organ Human on a Chip Systems to Predict in vivo Outcomes For Efficacy and Toxicity3D-Culture, Organoids and Tox Screening Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
The utilization of multi-organ human-on-a-chip or body-on-a-chip systems for toxicology and efficacy, that ultimately should lead to personalized medicine applications, is a topic that has received much attention recently for drug discovery and subsequent regulatory approval. Hesperos has been constructing these systems with up to 6 organs and have demonstrated long-term (>28 days) evaluation of drugs and compounds, that have shown similar response to results seen from clinical data or reports in the literature. Application of these systems for ALS, Alzheimer’s, rare diseases, diabetes and cardiac and skeletal muscle mechanistic toxicity will be reviewed. The development of an in vitro PDPK modeling that predicts in vivo results will also be presented. The system utilizes a pumpless platform with a serum free recirculating medium. This methodology integrates microsystems fabrication technology and surface modifications with protein and cellular components, for initiating and maintaining self-assembly and growth into biologically, mechanically and electronically interactive functional multi-component systems. Hesperos has received Phase II and Phase IIB SBIR grants from NCATS to apply Advanced Manufacturing Technologies and automation to these systems in collaboration with NIST in addition to support form pharmaceutical and cosmetic companies. This talk will also give results of six workshops held at NIH to explore what is needed for validation and qualification of these new systems.
Add to Calendar ▼2019-06-13 00:00:002019-06-14 00:00:00Europe/London3D-Culture, Organoids and Tox Screening Europe 20193D-Culture, Organoids and Tox Screening Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com